This dysregulation of serotonergic signaling, particularly via the 5-HT3 pathway, contributes to visceral hypersensitivity, which is a hallmark of IBS, and supports the use of 5-HT3 antagonists in symptom management, especially in diarrhea-predominant subtypes [14, 15]. Here, HTR3A is linked to irritable bowel syndrome.